Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 245

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 245
---
 259,936 (83,875) (32) % Contra R&D expenses (1,199,548) (989,716) (209,832) 21 % Total indirect R&D costs 4,666,281 4,960,589 (294,308) (6) % Total R&D expenses $ 14,205,208 $ 21,538,074 $ (7,332,866) (34) % (1) The applicable program(s) receive grant funding and/or the Tax Incentive. The amount of R&D expense for the period indicated is shown on a gross basis (i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (2) below. (2) These contra R&D expenses were recognized as follows for the years ended December 31, 2024 and 2023: (a) Ovaprene, $0.2 million, and $0, respectively; (b) Other advanced clinical stage programs, $0 and $0.1 million, respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $1.3 million and $0.9 million, respectively; and (d) Preclinical stage programs, $6.2 million and $7.9 million, respectively. The decrease of approximately $7.3 million in R&D expenses from 2023 to 2024 was primarily attributable to a decrease in costs related to development activities for Sildenafil Cream as a result of the completion of the Phase 2b RESPOND clinical study completed in June 2023, partially offset by increases in costs related to our ongoing pivotal Phase 3 clinical trial of Ovaprene and manufacturing and regulatory affairs activities for Ovaprene. Contra-R&D expenses for the years ended December 31, 2024 and 2023 primarily offset direct program costs for DARE-LARC1, one of our preclinical stage programs. License fee expenses For each of the years ended December 31, 2024 and December 31, 2023 we accrued or paid $100,000 of the annual license maintenance fee payable under our license agreement related to DARE-HRT1. For further discussion of this annual license maintenance fee, see Note 3 "Strategic Agreements—Strategic Agreements for Pipeline Development" to the accompanying consolidated financial statements. Other income (expense) Sale of royalty and milestone rights, net The $20.